Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
INSM submitted a Form 144 reporting proposed sales of Common stock. The filing, dated 05/04/2026, lists multiple sale entries by William Lewis with transaction dates from 02/03/2026 through 04/16/2026. The entries are recorded under "Stock Plan Activity" and identify Common shares to be sold on NASDAQ.
Insmed Inc reported a Schedule 13G filing showing Vanguard Capital Management beneficially owned 11,514,893 shares of Common Stock, representing 5.34% of the class as of 03/31/2026. The filer reports 1,872,762 shares of sole voting power and sole dispositive power over 11,514,893 shares.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in INSMED Inc. On April 16, 2026, he exercised options for 10,699 shares of Common Stock at exercise prices of $30.46 and $17.16 per share.
That same day he sold a total of 10,699 shares of Common Stock in open-market transactions at weighted average prices between $142.39 and $146.02 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions he directly held 301,185 shares, with an additional 233,924 shares held indirectly by a trust.
INSM reports proposed sales of Common stock on a Form 144, listing multiple sale dates and share counts attributable to William Lewis under stock plan activity. The filing lists transactions dated 04/06/2026, 03/19/2026, 03/05/2026, and earlier 2026 dates with corresponding numeric entries.
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales in Insmed common stock. On April 6, 2026, he exercised stock options for a total of 10,699 shares at strike prices of $30.46 and $17.16 per share, then sold 10,699 shares in open-market transactions at weighted average prices around $161.73, $163.23, and $164.01. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly owned about 301,185 shares of common stock, with an additional 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
Insmed Incorporated reported that its Phase 2b CEDAR trial of brensocatib in moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints, and the company will discontinue development of brensocatib for HS.
The randomized, double-blind, placebo-controlled study enrolled 214 patients across 72 global sites. At Week 16, abscess and inflammatory nodule counts fell 45.5% and 40.3% in the 10 mg and 40 mg brensocatib arms, compared with a 57.1% reduction on placebo, indicating no efficacy advantage. Safety was consistent with prior studies, with similar rates of treatment-emergent adverse events and no new safety signals at either dose.
INSM filed a Form 144 reporting proposed sales of Common stock and recent stock-plan related activity. The cover lists a proposed sale date of 04/06/2026 on NASDAQ and identifies William Lewis as the reporting seller. The filing itemizes multiple reported sales by William Lewis dated between 01/06/2026 and 03/19/2026, each with the disclosed reported share counts.
Insmed Inc Chief Operating Officer Roger Adsett exercised options to acquire 88,060 shares of common stock at an exercise price of $14.56 per share. On the same date, he sold 88,060 shares in open-market transactions at weighted average prices of $163.18, $164.11, and $164.95 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, he directly holds 106,810 shares of Insmed common stock.
INSM Section 144 notice reports proposed sales of Common stock by Roger Adsett. The filing lists four sales dates and share counts: 02/03/2026: 791 shares; 01/08/2026: 2,059 shares; 01/07/2026: 802 shares; 01/06/2026: 1,429 shares. The entries appear under "Securities Sold During The Past 3 Months" and are labeled as Stock Plan Activity.